

**ANALYSIS OF AGREEMENT CONTAINING  
CONSENT ORDERS TO AID PUBLIC COMMENT**

**I. Introduction**

The Federal Trade Commission (“Commission”) has accepted for public comment,

The Acquisition would likely substantially lessen competition in the relevant markets.  
The U.S. markets for balloon sinus dilat

after Hemostasis acquires the divestiture assets. For the seven years following the initial three-year period, the proposed Order requires Hemostasis to obtain prior approval from the Commission before transferring any of the divested assets to any buyer engaged in the research, development, manufacture, marketing, or sale of any balloon sinus dilation products or ENT navigation systems.

The purpose of this analysis is to facilitate public comment on the Consent Agreement, and the Commission does not intend this analysis to constitute an official interpretation of the proposed Order or to modify its terms in any way.